← Back to Search

Other

Preoperative Maltodextrin for Heart Failure

Phase 4
Waitlist Available
Led By Matthew Cameron, MDCM, MPH
Research Sponsored by Jewish General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years of age or older
Presenting for coronary artery bypass grafting surgery
Must not have
Dysphagia
Celiac disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up first 1-48 hours after surgery
Awards & highlights

Summary

This trial tests if giving a carbohydrate drink (Maltodextrin) before heart surgery can help patients with weak hearts. The goal is to see if this drink improves heart function and recovery by giving the heart extra energy.

Who is the study for?
This trial is for adults over 18 who are scheduled for coronary artery bypass grafting surgery and have a left ventricular ejection fraction below 50%. It's specifically for surgeries starting at 7:30 am. People with swallowing difficulties, slow stomach emptying, intolerance to oral intake, celiac disease, or type 1 diabetes cannot participate.
What is being tested?
The study is testing if drinking a Maltodextrin solution before heart surgery can help maintain cardiac function better than a placebo. Patients are randomly assigned to one of the two groups without knowing which one they're in (double-blinded).
What are the potential side effects?
Potential side effects from the Maltodextrin solution could include digestive issues due to its sugar content but specific side effects related to heart function will be closely monitored given the condition of participants.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I am scheduled for surgery to improve blood flow to my heart.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have difficulty swallowing.
Select...
I have celiac disease.
Select...
I have been diagnosed with gastroparesis.
Select...
I have Type 1 diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 48 hours after surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 48 hours after surgery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Intraoperative three-dimensional left ventricular ejection fraction (3-D LVEF)
Secondary study objectives
Cardiac Index
E/e' ratio
Hospital Length of Stay
+11 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Intervention GroupExperimental Treatment1 Intervention
Patients in the intervention group will receive an oral preparation of 50 grams of Maltodextrin solution mixed in 400 millilitres (mL) of water twice the night before surgery and within 2-3 hours before surgery. The entire drink is meant to be consumed within 15 minutes.
Group II: Placebo GroupPlacebo Group1 Intervention
Patients in the intervention group will receive a placebo in 400 millilitres (mL) of water twice the night before surgery and within 2-3 hours before surgery. The entire drink is meant to be consumed within 15 minutes.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Left Ventricular Dysfunction (LVD) work by enhancing the heart's pumping ability and reducing its workload. Medications such as ACE inhibitors, beta-blockers, and diuretics improve heart muscle contractility, lower blood pressure, and manage fluid balance, respectively. Treatments like the Maltodextrin solution provide a readily available source of glucose, supporting cardiac function by improving the energy supply to the heart muscle. This is vital for LVD patients as it helps maintain adequate cardiac output and prevents further deterioration of heart function.
Manipulation of the gut microbiota by the use of prebiotic fibre does not override a genetic predisposition to heart failure.

Find a Location

Who is running the clinical trial?

Jewish General HospitalLead Sponsor
140 Previous Clinical Trials
278,498 Total Patients Enrolled
Matthew Cameron, MDCM, MPHPrincipal InvestigatorMcGill University

Media Library

Maltodextrin solution (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05188222 — Phase 4
Left Ventricular Dysfunction Research Study Groups: Intervention Group, Placebo Group
Left Ventricular Dysfunction Clinical Trial 2023: Maltodextrin solution Highlights & Side Effects. Trial Name: NCT05188222 — Phase 4
Maltodextrin solution (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05188222 — Phase 4
~47 spots leftby Sep 2025